Pub Date : 2024-06-07DOI: 10.2174/0115748855299918240529063242
Meghna Dheek, Shikha Baghel Chauhan, Indu Singh
Emulsomes have gained attention because they are a novel lipoidal vesicular system that has an internal solid fat core surrounded by a phospholipid bilayer. Cancer is a complex and broad term that refers to a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. In the context of cancer targeting, emulsomes have shown promising potential due to their ability to improve the solubility, stability, and bioavailability of anticancer drugs, leading to enhanced therapeutic efficacy and reduced systemic toxicity. This article addresses emulsomal composition, preparation techniques, and different kinds of emulsomes loaded with drugs like fluvastatin and raloxifene hydrochloride to target cancer cells. The use of emulsomes in cancer targeting holds great promise for improving the precision, efficacy, and safety of cancer treatments. A comprehensive search of relevant scientific literature was performed. This involved searching databases such as PubMed, Scopus, Web of Science, and others to identify relevant studies, articles, and reviews related to the topic. Emulsomes loaded with specific drugs show promising results in cancer treatment. Examples include piceatannol-loaded emulsomes for colon cancer, raloxifene hydrochloride-loaded emulsomes for breast cancer, and fluvastatin-loaded emulsomes for prostate cancer. Emulsomes represent a cutting-edge approach to cancer drug delivery, offering a versatile and effective solution to address challenges associated with traditional anticancer formulations. Ongoing research holds promise for the continued development of personalized cancer therapy.
乳状液体是一种新型的类脂囊泡系统，内部有一个由磷脂双分子层包围的固体脂肪核心，因此备受关注。癌症是一个复杂而宽泛的术语，指的是一组以异常细胞在体内不受控制地生长和扩散为特征的疾病。在癌症靶向治疗方面，乳状液因其能够提高抗癌药物的溶解度、稳定性和生物利用度，从而提高疗效并降低全身毒性，已显示出广阔的应用前景。本文介绍了乳状液的组成、制备技术，以及不同类型的乳状液载药（如氟伐他汀和盐酸雷洛昔芬）靶向治疗癌细胞的情况。乳状液在癌症靶向治疗中的应用为提高癌症治疗的精确性、有效性和安全性带来了巨大希望。我们对相关科学文献进行了全面搜索，包括搜索 PubMed、Scopus、Web of Science 等数据库，以确定与该主题相关的研究、文章和综述。乳状液是治疗癌症药物递送的前沿方法，为解决传统抗癌制剂所面临的挑战提供了一种多用途的有效解决方案。正在进行的研究为继续开发个性化癌症疗法带来了希望。
{"title":"Nanosphere Precision: Emulsomes Revolutionizing Cancer Targeted Therapy","authors":"Meghna Dheek, Shikha Baghel Chauhan, Indu Singh","doi":"10.2174/0115748855299918240529063242","DOIUrl":"https://doi.org/10.2174/0115748855299918240529063242","url":null,"abstract":"\u0000\u0000Emulsomes have gained attention because they are a novel lipoidal vesicular system that\u0000has an internal solid fat core surrounded by a phospholipid bilayer. Cancer is a complex and broad\u0000term that refers to a group of diseases characterized by the uncontrolled growth and spread of abnormal\u0000cells in the body. In the context of cancer targeting, emulsomes have shown promising potential\u0000due to their ability to improve the solubility, stability, and bioavailability of anticancer drugs, leading\u0000to enhanced therapeutic efficacy and reduced systemic toxicity.\u0000This article addresses emulsomal composition, preparation techniques, and different kinds of emulsomes\u0000loaded with drugs like fluvastatin and raloxifene hydrochloride to target cancer cells. The use\u0000of emulsomes in cancer targeting holds great promise for improving the precision, efficacy, and safety\u0000of cancer treatments.\u0000A comprehensive search of relevant scientific literature was performed. This involved searching databases\u0000such as PubMed, Scopus, Web of Science, and others to identify relevant studies, articles,\u0000and reviews related to the topic.\u0000Emulsomes loaded with specific drugs show promising results in cancer treatment. Examples include\u0000piceatannol-loaded emulsomes for colon cancer, raloxifene hydrochloride-loaded emulsomes for\u0000breast cancer, and fluvastatin-loaded emulsomes for prostate cancer.\u0000Emulsomes represent a cutting-edge approach to cancer drug delivery, offering a versatile and effective\u0000solution to address challenges associated with traditional anticancer formulations. Ongoing research\u0000holds promise for the continued development of personalized cancer therapy.\u0000","PeriodicalId":11004,"journal":{"name":"Current Drug Therapy","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2024-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141373225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
This article explores the well-established therapeutic attributes of honey and garlic, renowned for their potent antibacterial effects. This investigation aims to elucidate the synergistic antibacterial potential resulting from the combined use of these two natural substances. A comprehensive examination of honey's antibacterial and antifungal characteristics is conducted, delineating its intricate mechanism of action with a focus on hydrogen peroxide and other phytochemicals. Simultaneously, various processes underpinning the antibacterial properties of garlic are discussed, with particular emphasis on its key bioactive component, allicin. This research unveils a novel perspective on the interaction between honey and garlic. It is intricately analyzed how garlic's bioactive components disrupt microbial cell membranes, while honey employs diverse tactics to combat illnesses. This interaction opens new possibilities for modern antibacterial approaches. Quantitative findings and the significance of the study are discussed in detail. The practical applications of the synergistic antibacterial potential are underscored, emphasizing its relevance in food preservation and medicinal contexts. The research accentuates the promising use of garlic and honey blends as natural alternatives to artificial preservatives, with implications for wound care and infection prevention. Emphasizing the valuable applications of synergistic antibacterial potential across diverse industries, including food preservation and medicine, this study underscores the importance of harnessing the combined antibacterial qualities of garlic and honey as a sustainable solution to emerging challenges in food safety and health.
{"title":"Exploring the Synergistic Antimicrobial Potential of Garlic and Honey: A\u0000Comprehensive Review","authors":"Priti Yadav, Surendra Lalwani, D. Chanchal, Nidhi Mittal, Jitendra Singh Chaudhary","doi":"10.2174/0115748855287440240529080448","DOIUrl":"https://doi.org/10.2174/0115748855287440240529080448","url":null,"abstract":"\u0000\u0000This article explores the well-established therapeutic attributes of honey and garlic,\u0000renowned for their potent antibacterial effects. This investigation aims to elucidate the synergistic\u0000antibacterial potential resulting from the combined use of these two natural substances.\u0000\u0000\u0000\u0000A comprehensive examination of honey's antibacterial and antifungal characteristics is conducted, delineating its intricate mechanism of action with a focus on hydrogen peroxide and other\u0000phytochemicals. Simultaneously, various processes underpinning the antibacterial properties of garlic\u0000are discussed, with particular emphasis on its key bioactive component, allicin.\u0000\u0000\u0000\u0000This research unveils a novel perspective on the interaction between honey and garlic. It is\u0000intricately analyzed how garlic's bioactive components disrupt microbial cell membranes, while\u0000honey employs diverse tactics to combat illnesses. This interaction opens new possibilities for modern\u0000antibacterial approaches.\u0000\u0000\u0000\u0000Quantitative findings and the significance of the study are discussed in detail. The practical applications of the synergistic antibacterial potential are underscored, emphasizing its relevance\u0000in food preservation and medicinal contexts. The research accentuates the promising use of garlic and\u0000honey blends as natural alternatives to artificial preservatives, with implications for wound care and\u0000infection prevention.\u0000\u0000\u0000\u0000Emphasizing the valuable applications of synergistic antibacterial potential across diverse industries, including food preservation and medicine, this study underscores the importance of\u0000harnessing the combined antibacterial qualities of garlic and honey as a sustainable solution to emerging challenges in food safety and health.\u0000","PeriodicalId":11004,"journal":{"name":"Current Drug Therapy","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2024-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141377251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alzheimer's disease is a neurological condition that is becoming increasingly common and is typified by dementia. Drug development for AD is a major issue with a startlingly high failure rate despite a marked increase in the frequency of the disease linked to genetic factors. As AD is the most common neurological illness and contributes to both the high patient burden and the cost of healthcare, this issue must be addressed. The current manuscript aims to focus on the current treatment approaches of newer drugs under clinical trials of Alzheimer’s disease by targeting the various pathological pathways that are involved in AD. Data provided in this review are from literature surveys and ongoing clinical trials from reputed search engines like PubMed, ResearchGate, Science Direct, and Google Scholar, as well as from various respected authors and—registered websites such as memory.ucsf.edu/genetics/familial-Alzheimer’s- disease and https://www.clinicaltrials.gov. There are diverse forms of drugs and multiple pathways on which many advancements and clinical trials have been conductedand are undergoing. Various investigations and studies are going on. There are different pathogenesis of AD, such as Tau, vascular, Amyloid β, estrogen deficiency, and the role of gut microbiota in AD. Donepezil, Rivastigmine, etc., are currently used for treatment, and certain drugs are in different stages of clinical trials, such as ANI792, ACC-001, CAD106 &ABvac40, and it is concluded that after successful trials of the new drugs, they can be used for the treatment of AD with maximum benefits and less side effect.
{"title":"Current Treatment Approaches for Alzheimer’s Disease and Possible Drug Targets","authors":"Ashutosh Ranjan, Shashikesh Shukla, Shamsher Singh","doi":"10.2174/0115748855307998240529063710","DOIUrl":"https://doi.org/10.2174/0115748855307998240529063710","url":null,"abstract":"\u0000\u0000Alzheimer's disease is a neurological condition that is becoming increasingly common and\u0000is typified by dementia. Drug development for AD is a major issue with a startlingly high failure rate\u0000despite a marked increase in the frequency of the disease linked to genetic factors. As AD is the most\u0000common neurological illness and contributes to both the high patient burden and the cost of\u0000healthcare, this issue must be addressed.\u0000The current manuscript aims to focus on the current treatment approaches of newer drugs under clinical\u0000trials of Alzheimer’s disease by targeting the various pathological pathways that are involved in\u0000AD.\u0000Data provided in this review are from literature surveys and ongoing clinical trials from reputed\u0000search engines like PubMed, ResearchGate, Science Direct, and Google Scholar, as well as from\u0000various respected authors and—registered websites such as memory.ucsf.edu/genetics/familial-Alzheimer’s-\u0000disease and https://www.clinicaltrials.gov.\u0000There are diverse forms of drugs and multiple pathways on which many advancements and clinical\u0000trials have been conductedand are undergoing. Various investigations and studies are going on.\u0000There are different pathogenesis of AD, such as Tau, vascular, Amyloid β, estrogen deficiency, and\u0000the role of gut microbiota in AD. Donepezil, Rivastigmine, etc., are currently used for treatment, and\u0000certain drugs are in different stages of clinical trials, such as ANI792, ACC-001, CAD106 &ABvac40,\u0000and it is concluded that after successful trials of the new drugs, they can be used for the treatment\u0000of AD with maximum benefits and less side effect.\u0000","PeriodicalId":11004,"journal":{"name":"Current Drug Therapy","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2024-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141386881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-10DOI: 10.2174/0115748855294736240502073344
Hiren V. Patel, Nayankumar C. Ratnakar, Himanshu Paliwal, B. Prajapati
Lornoxicam is a potent non-steroidal anti-inflammatory drug (NSAID) with strong analgesic properties; however, its short half-life necessitates frequent administration for sustained efficacy. The objective of the present study was to identify critical formulation parameters affecting sustained release Eudragit RSPO microsphere of lornoxicam employing the concept of design of experiments The lornoxicam-loaded microspheres were prepared using a spray drying technique by optimizing the drug:polymer ratio(X1) and inlet air temperature (X2) using a 32 full factorial design. The percentage drug entrapment (Y1), percentage yield (Y2) and cumulative percentage of the drug dissolved at 18 hr (Y3) were selected as dependent variables. Microspheres were evaluated for percentage drug entrapment, mean particle size, percentage yield, in vitro drug release study and scanning electron microscopy (SEM). The optimized batch showed 84.51% drug release after 18 h with significantly higher drug entrapment and percentage yield. The optimization was further verified using overlay and desirability plots. The sustained release behavior of the drug from microspheres in GIT was displayed. The predicted and observed responses for the optimized formulation were in close agreement with the release profile of the drug. The sustained release microspheres of lornoxicam may prove to be an effective analgesic with excellent anti-inflammatory potential.
{"title":"Fabrication and Characterization of Sustained-Release Eudragit RSPO\u0000Microsphere of Lornoxicam by Spray Drying Technique","authors":"Hiren V. Patel, Nayankumar C. Ratnakar, Himanshu Paliwal, B. Prajapati","doi":"10.2174/0115748855294736240502073344","DOIUrl":"https://doi.org/10.2174/0115748855294736240502073344","url":null,"abstract":"\u0000\u0000Lornoxicam is a potent non-steroidal anti-inflammatory drug (NSAID) with\u0000strong analgesic properties; however, its short half-life necessitates frequent administration for sustained efficacy.\u0000\u0000\u0000\u0000The objective of the present study was to identify critical formulation parameters affecting\u0000sustained release Eudragit RSPO microsphere of lornoxicam employing the concept of design of experiments\u0000\u0000\u0000\u0000The lornoxicam-loaded microspheres were prepared using a spray drying technique by optimizing the drug:polymer ratio(X1) and inlet air temperature (X2) using a 32 full factorial design.\u0000The percentage drug entrapment (Y1), percentage yield (Y2) and cumulative percentage of the drug\u0000dissolved at 18 hr (Y3) were selected as dependent variables. Microspheres were evaluated for percentage drug entrapment, mean particle size, percentage yield, in vitro drug release study and scanning electron microscopy (SEM).\u0000\u0000\u0000\u0000The optimized batch showed 84.51% drug release after 18 h with significantly higher drug\u0000entrapment and percentage yield. The optimization was further verified using overlay and desirability\u0000plots. The sustained release behavior of the drug from microspheres in GIT was displayed. The predicted and observed responses for the optimized formulation were in close agreement with the release\u0000profile of the drug.\u0000\u0000\u0000\u0000The sustained release microspheres of lornoxicam may prove to be an effective analgesic\u0000with excellent anti-inflammatory potential.\u0000","PeriodicalId":11004,"journal":{"name":"Current Drug Therapy","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2024-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140994097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-24DOI: 10.2174/0115748855308697240409035903
Naina Mohamed Pakkir Maideen, Sultan Al Rashid, M. Gobinath, Mohamed Harshath Jahir Hussain
Pregnant women may experience low back pain and other pain symptoms, fever, and inflammatory conditions that may harm the fetus and mother if left untreated. The most common uses of non-steroidal anti-inflammatory drugs (NSAIDs) are the treatment of inflammation, pain and pyrexia. However, after 20-30 weeks of gestation, using NSAIDs during pregnancy may cause oligohydramnios and premature ductus arteriosus closure, which could harm the developing fetus. The purpose of this review article is to critically examine the clinical evidence that is currently available for oligohydramnios and premature ductus arteriosus closure linked to NSAIDs. Online databases such as Medline/Pubmed/PMC, EBSCOhost, Scopus, Web of science, Embase, Science Direct, Google Scholar, and reference lists were searched to identify articles which dealt with NSAIDs-associated oligohydramnios and premature closure of ductus arteriosus. Numerous regulatory agencies released warnings about oligohydramnios and premature closure of ductus arteriosus linked to NSAIDs. Furthermore, a number of case reports, case series, and some observational studies have also been published about the possibility of oligohydramnios and premature closure of ductus arteriosus linked to NSAIDs use. Women who are pregnant for 20 weeks or more should refrain from self-medicating with NSAIDs without consulting a pharmacist or a physician. The use of NSAIDs during pregnancy should carefully be considered due to potential risks to the mother and developing fetus, especially after 20-30 weeks of gestation. To guarantee the best possible health for the expectant mother and the unborn child, healthcare professionals should weigh the benefits and risks and look into alternate options. Pregnant women may opt for acetaminophen (paracetamol) to relieve pain and fever during pregnancy. Pregnant women should seek medical attention if there is persisting pain for more than three days.
{"title":"Oligohydramnios and Intrauterine Premature Closure of Ductus Arteriosus Associated with the Use of NSAIDs During Pregnancy – An Overview of Clinical Evidence","authors":"Naina Mohamed Pakkir Maideen, Sultan Al Rashid, M. Gobinath, Mohamed Harshath Jahir Hussain","doi":"10.2174/0115748855308697240409035903","DOIUrl":"https://doi.org/10.2174/0115748855308697240409035903","url":null,"abstract":"\u0000\u0000Pregnant women may experience low back pain and other pain symptoms,\u0000fever, and inflammatory conditions that may harm the fetus and mother if left untreated. The most\u0000common uses of non-steroidal anti-inflammatory drugs (NSAIDs) are the treatment of inflammation,\u0000pain and pyrexia. However, after 20-30 weeks of gestation, using NSAIDs during pregnancy may\u0000cause oligohydramnios and premature ductus arteriosus closure, which could harm the developing\u0000fetus.\u0000\u0000\u0000\u0000The purpose of this review article is to critically examine the clinical evidence that is\u0000currently available for oligohydramnios and premature ductus arteriosus closure linked to NSAIDs.\u0000\u0000\u0000\u0000Online databases such as Medline/Pubmed/PMC, EBSCOhost, Scopus, Web of science,\u0000Embase, Science Direct, Google Scholar, and reference lists were searched to identify articles which\u0000dealt with NSAIDs-associated oligohydramnios and premature closure of ductus arteriosus.\u0000\u0000\u0000\u0000Numerous regulatory agencies released warnings about oligohydramnios and premature closure\u0000of ductus arteriosus linked to NSAIDs. Furthermore, a number of case reports, case series, and\u0000some observational studies have also been published about the possibility of oligohydramnios and\u0000premature closure of ductus arteriosus linked to NSAIDs use.\u0000\u0000\u0000\u0000Women who are pregnant for 20 weeks or more should refrain from self-medicating\u0000with NSAIDs without consulting a pharmacist or a physician. The use of NSAIDs during pregnancy\u0000should carefully be considered due to potential risks to the mother and developing fetus, especially\u0000after 20-30 weeks of gestation. To guarantee the best possible health for the expectant mother and the\u0000unborn child, healthcare professionals should weigh the benefits and risks and look into alternate\u0000options. Pregnant women may opt for acetaminophen (paracetamol) to relieve pain and fever during\u0000pregnancy. Pregnant women should seek medical attention if there is persisting pain for more than\u0000three days.\u0000","PeriodicalId":11004,"journal":{"name":"Current Drug Therapy","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2024-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140661726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-24DOI: 10.2174/0115748855297767240408053500
Rishav Sharma, R. Malviya, Prerna Uniyal, Bhupendra Prajapati
The integration of artificial intelligence and machine learning holds great promise for enhancing healthcare institutions and providing fresh perspectives on the origins and advancement of long-term illnesses. In the healthcare sector, artificial intelligence and machine learning are used to address supply and demand concerns, genomic applications, and new advancements in drug development, cancer, and heart disease. The article explores the ways that machine learning, AI, precision medicine, and genomics are changing healthcare. The essay also discusses how AI's examination of various patient data could enhance healthcare institutions, provide fresh insights into chronic conditions, and advance precision medicine. The potential uses of machine learning for genome analysis are also examined in the paper, particularly about genetic biomarker-based disease risk and symptom prediction. The challenges posed by the phenotype-genotype relationship are examined, as well as the significance of comprehending disease pathways in order to create tailored treatments. Moreover, it offers a streamlined and modularized method that predicts how genotypes affect cell properties using machine-learning models, enabling the development of personalized drugs. The collective feedback highlights the rapid interdisciplinary growth of medical genomics following the completion of the Human Genome Project. It also emphasizes how important genomic data is for improving healthcare outcomes and facilitating personalized medicine. The study's conclusions point to a revolutionary shift in healthcare: the application of AI/ML to illness control. Even though these innovations have a lot of potential benefits, problems like algorithm interpretability and ethical issues need to be worked out before they can be successfully incorporated into routine medical practice. Using machine learning in medicine has enormous potential benefits for the biotech industry. Further research, ongoing regulatory frameworks, and collaboration between medical professionals and data analysts are necessary to fully utilize machine learning as well as artificial intelligence in disease management.
{"title":"A State-of-the-art Review on Artificial Intelligence and Machine Learning Applications","authors":"Rishav Sharma, R. Malviya, Prerna Uniyal, Bhupendra Prajapati","doi":"10.2174/0115748855297767240408053500","DOIUrl":"https://doi.org/10.2174/0115748855297767240408053500","url":null,"abstract":"\u0000\u0000The integration of artificial intelligence and machine learning holds great\u0000promise for enhancing healthcare institutions and providing fresh perspectives on the origins and\u0000advancement of long-term illnesses. In the healthcare sector, artificial intelligence and machine learning\u0000are used to address supply and demand concerns, genomic applications, and new advancements\u0000in drug development, cancer, and heart disease.\u0000\u0000\u0000\u0000The article explores the ways that machine learning, AI, precision medicine, and genomics\u0000are changing healthcare. The essay also discusses how AI's examination of various patient data could\u0000enhance healthcare institutions, provide fresh insights into chronic conditions, and advance precision\u0000medicine. The potential uses of machine learning for genome analysis are also examined in the paper,\u0000particularly about genetic biomarker-based disease risk and symptom prediction.\u0000\u0000\u0000\u0000The challenges posed by the phenotype-genotype relationship are examined, as well as\u0000the significance of comprehending disease pathways in order to create tailored treatments. Moreover,\u0000it offers a streamlined and modularized method that predicts how genotypes affect cell properties\u0000using machine-learning models, enabling the development of personalized drugs. The collective feedback\u0000highlights the rapid interdisciplinary growth of medical genomics following the completion of\u0000the Human Genome Project. It also emphasizes how important genomic data is for improving\u0000healthcare outcomes and facilitating personalized medicine.\u0000\u0000\u0000\u0000The study's conclusions point to a revolutionary shift in healthcare: the application of\u0000AI/ML to illness control. Even though these innovations have a lot of potential benefits, problems\u0000like algorithm interpretability and ethical issues need to be worked out before they can be successfully\u0000incorporated into routine medical practice. Using machine learning in medicine has enormous potential\u0000benefits for the biotech industry. Further research, ongoing regulatory frameworks, and collaboration\u0000between medical professionals and data analysts are necessary to fully utilize machine learning\u0000as well as artificial intelligence in disease management.\u0000","PeriodicalId":11004,"journal":{"name":"Current Drug Therapy","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2024-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140661923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-19DOI: 10.2174/0115748855287311240416050237
D. Lu, Ting-Ren Lu
The impact and burden of coronavirus outbreak (COVID-19, SARS-CoV-2) still exists worldwide. Different knowledge, opinions, and techniques determine the various outcomes and potency of preventive and therapeutic strategies. COVID-19 infections, long COVID, and the complexity of treatment variability are challenging issues for therapeutic promotion and cost-effective consideration. To speed up global efforts against COVID-19, clinical diagnosis, therapeutic selections, and drug combination studies should be optimized in different ways. The epidemic condition, vaccination, techniques, and therapeutic options are open to new expeditions. To target infectious and therapeutic variability, biomedical mechanisms and pathways should be understood. Facilitating and enhancing new global machinery and roadmap against viral-induced social damages and potential epidemics should be established for biological and pharmaceutical purposes. Thus, in this study, the ways of medical translation for COVID-19 treatment are discussed.
{"title":"COVID-19 Study: A New Principle Discovery","authors":"D. Lu, Ting-Ren Lu","doi":"10.2174/0115748855287311240416050237","DOIUrl":"https://doi.org/10.2174/0115748855287311240416050237","url":null,"abstract":"\u0000\u0000The impact and burden of coronavirus outbreak (COVID-19, SARS-CoV-2) still exists\u0000worldwide. Different knowledge, opinions, and techniques determine the various outcomes and potency\u0000of preventive and therapeutic strategies. COVID-19 infections, long COVID, and the complexity\u0000of treatment variability are challenging issues for therapeutic promotion and cost-effective consideration.\u0000To speed up global efforts against COVID-19, clinical diagnosis, therapeutic selections,\u0000and drug combination studies should be optimized in different ways. The epidemic condition, vaccination,\u0000techniques, and therapeutic options are open to new expeditions. To target infectious and\u0000therapeutic variability, biomedical mechanisms and pathways should be understood. Facilitating and\u0000enhancing new global machinery and roadmap against viral-induced social damages and potential\u0000epidemics should be established for biological and pharmaceutical purposes. Thus, in this study, the\u0000ways of medical translation for COVID-19 treatment are discussed.\u0000","PeriodicalId":11004,"journal":{"name":"Current Drug Therapy","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2024-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140684793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-18DOI: 10.2174/0115748855287070240409061220
Yikuan Du, Xianhong Chi, Qianwen Chen, Yue Xiao, Zhendong Ma, Zhenjie Wang, Zhuoming Guo, Peng Chen, Zilin Chen, Mengting Zhang, Jinyan Guo, YuQi Zhou, Chun Yang
Banxia Xiexin decoration (BXD), a complex prescription in Traditional Chinese Medicine (TCM), clinically acts as a treatment for gastritis and diabetes while its mechanism of treatment remains unknown. This study aimed to explore the common mechanism of BXD in treating gastritis and diabetes based on network pharmacology and molecular docking technology. The seven Chinese herbal components and drug targets were collected from the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) for gastritis and diabetes using GeneCards, DisGeNET, Comparative Toxicogenomics Database (CTD), and Online Mendelian Inheritance in Man (OMIM) databases. Common drug and disease targets were imported into the STRING data platform for protein-protein interaction (PPI) analysis, and Cytoscape 3.7.2 software for network topology analysis, and core targets were filtered. There were 124 components, 249 targets, 449 targets for gastritis, and 4005 targets for diabetes. After mapping, 83 BXD targets for gastritis and diabetes were obtained, and the targets with high correlation were STAT 3, JUN, TNF, IL-6, etc. More relevant targets were involved in the cancer pathway, AGE-RAGE signaling pathway of diabetic complications, fluid shear stress, and atherosclerosis pathway. This study preliminarily reveals that BXD may play a role in the treatment of gastritis and diabetes mellitus through multi-components, multi-targets, and multi-pathways, and proposes some potential "component-target-pathway" hypotheses in light of previous reports.
半夏泻心汤（BXD）是一种中药复方制剂，临床上主要用于治疗胃炎和糖尿病，但其治疗机制尚不清楚。本研究利用GeneCards、DisGeNET、比较毒物基因组学数据库（CTD）和OnlineMendelian Inheritance in Man（OMIM）数据库，从中药系统药理学数据库和分析平台（TCMSP）中收集了七种中药成分和药物靶点，并将其导入到中药系统药理学数据库和分析平台。经图谱分析，胃炎和糖尿病共有83个BXD靶点，相关性较高的靶点有STAT 3、JUN、TNF、IL-6等。本研究初步揭示了BXD可能通过多成分、多靶点、多通路在胃炎和糖尿病的治疗中发挥作用，并结合之前的报道提出了一些潜在的 "成分-靶点-通路 "假说。
{"title":"Investigating the Mechanism of Banxia Xiexin Decoction in Treating Gastritis and Diabetes Mellitus through Network Pharmacology and\u0000Molecular Docking Analysis","authors":"Yikuan Du, Xianhong Chi, Qianwen Chen, Yue Xiao, Zhendong Ma, Zhenjie Wang, Zhuoming Guo, Peng Chen, Zilin Chen, Mengting Zhang, Jinyan Guo, YuQi Zhou, Chun Yang","doi":"10.2174/0115748855287070240409061220","DOIUrl":"https://doi.org/10.2174/0115748855287070240409061220","url":null,"abstract":"\u0000\u0000Banxia Xiexin decoration (BXD), a complex prescription in Traditional Chinese\u0000Medicine (TCM), clinically acts as a treatment for gastritis and diabetes while its mechanism of\u0000treatment remains unknown.\u0000\u0000\u0000\u0000This study aimed to explore the common mechanism of BXD in treating gastritis and\u0000diabetes based on network pharmacology and molecular docking technology.\u0000\u0000\u0000\u0000The seven Chinese herbal components and drug targets were collected from the Traditional\u0000Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) for gastritis and\u0000diabetes using GeneCards, DisGeNET, Comparative Toxicogenomics Database (CTD), and Online\u0000Mendelian Inheritance in Man (OMIM) databases. Common drug and disease targets were imported\u0000into the STRING data platform for protein-protein interaction (PPI) analysis, and Cytoscape 3.7.2\u0000software for network topology analysis, and core targets were filtered.\u0000\u0000\u0000\u0000There were 124 components, 249 targets, 449 targets for gastritis, and 4005 targets for diabetes.\u0000After mapping, 83 BXD targets for gastritis and diabetes were obtained, and the targets with\u0000high correlation were STAT 3, JUN, TNF, IL-6, etc. More relevant targets were involved in the cancer\u0000pathway, AGE-RAGE signaling pathway of diabetic complications, fluid shear stress, and atherosclerosis\u0000pathway.\u0000\u0000\u0000\u0000This study preliminarily reveals that BXD may play a role in the treatment of gastritis\u0000and diabetes mellitus through multi-components, multi-targets, and multi-pathways, and proposes\u0000some potential \"component-target-pathway\" hypotheses in light of previous reports.\u0000","PeriodicalId":11004,"journal":{"name":"Current Drug Therapy","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2024-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140687384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mechanistic investigations in both animal models and human subjects have consistently elucidated a causal relationship between obesity, diabetes, and Alzheimer's disease (AD). Alzheimer's disease is the predominant etiology of dementia, marked by progressive cerebral degeneration char-acterized by the formation of intracellular neurofibrillary tangles and extracellular amyloid beta (Aβ) plaques. Adipose tissue secretes bioactive signaling molecules known as adipokines. Interactions be-tween adipose tissue and the central nervous system serve as the foundational mechanism contrib-uting to the elevated susceptibility of individuals with obesity to the onset of neurologic disorders, including cognitive and mood-related disturbances. Omentin is a recently discovered adipokine that has gained attention for study because of its pleiotropic effects on several disorders. The specific receptor responsible for binding with Omentin remains unidentified thus far. This investigation elu-cidates the variability in Omentin levels observed in multiple pathological conditions. Therapeutic methods to raise omentin-1 levels may be helpful for the treatment or prevention of several illnesses. Increases in circulating omentin-1 levels can be achieved with weight loss, an olive oil-rich diet, aerobic exercise, atorvastatin therapy, and the use of diabetes medications. It is also possible to use circulating omentin-1 as a biomarker of obesity, diabetes, metabolic syndrome, atherosclerosis, is-chemic heart disease, inflammatory disease, cancer, and neurological diseases via AMP-activated protein kinase/Akt/nuclear factor-κB/mitogen-activated protein kinase (ERK, JNK, and p38) signal-ing. This review provides insights into the potential use of omentin-1 as a biomarker for Obesity, Diabetes, and associated metabolic and neurological disorders.
{"title":"Omentin 1: A Promising Regulator and Therapeutic Target in the Battle against Obesity, Diabetes, and Alzheimer’s Disease","authors":"Shiv Kumar Kushawaha, Radhika Sharma, Mahendra Singh Ashawat","doi":"10.2174/0115748855296758240408040336","DOIUrl":"https://doi.org/10.2174/0115748855296758240408040336","url":null,"abstract":"\u0000\u0000Mechanistic investigations in both animal models and human subjects have consistently elucidated a causal relationship between obesity, diabetes, and Alzheimer's disease (AD). Alzheimer's disease is the predominant etiology of dementia, marked by progressive cerebral degeneration char-acterized by the formation of intracellular neurofibrillary tangles and extracellular amyloid beta (Aβ) plaques. Adipose tissue secretes bioactive signaling molecules known as adipokines. Interactions be-tween adipose tissue and the central nervous system serve as the foundational mechanism contrib-uting to the elevated susceptibility of individuals with obesity to the onset of neurologic disorders, including cognitive and mood-related disturbances. Omentin is a recently discovered adipokine that has gained attention for study because of its pleiotropic effects on several disorders. The specific receptor responsible for binding with Omentin remains unidentified thus far. This investigation elu-cidates the variability in Omentin levels observed in multiple pathological conditions. Therapeutic methods to raise omentin-1 levels may be helpful for the treatment or prevention of several illnesses. Increases in circulating omentin-1 levels can be achieved with weight loss, an olive oil-rich diet, aerobic exercise, atorvastatin therapy, and the use of diabetes medications. It is also possible to use circulating omentin-1 as a biomarker of obesity, diabetes, metabolic syndrome, atherosclerosis, is-chemic heart disease, inflammatory disease, cancer, and neurological diseases via AMP-activated protein kinase/Akt/nuclear factor-κB/mitogen-activated protein kinase (ERK, JNK, and p38) signal-ing. This review provides insights into the potential use of omentin-1 as a biomarker for Obesity, Diabetes, and associated metabolic and neurological disorders.\u0000","PeriodicalId":11004,"journal":{"name":"Current Drug Therapy","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140698831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-16DOI: 10.2174/0115748855283065240403073316
Zeid Zerehsaz, M. Yaghoubi, Ali Teimouri, Zohreh Mousavi, Mona Najaf Najafi, Ali Moradi, Masoud Mohebbi, A. Sahebkar
Evaluating the Effect of Selenium Supplementation on Thyroid Nodule Volume in Euthyroid Patients Selenium is an essential trace element, which plays a role in regulation of the metabolism of thyroid hormones. This study was designed to evaluate the effect of selenium on the volume of thyroid nodules in euthyroid patients. In this triple-blinded clinical trial, a total of 60 euthyroid patients with benign thyroid nodules (solitary or multinodular goiter) and normal serum selenium were randomly divided into the case and control (n=30 each) groups. The case group received selenium 200 μg/day while the control group received placebo for 3 months. Thyroid ultrasound was used to measure thyroid nodule volume. Selenium supplementation (200 µg/day) retained the serum selenium levels of participants in the case group (P=0.251), while, the control group showed a significant drop in serum selenium levels (P=0.007). Moreover, the thyroid volume in case group showed a significant decrease after selenium supplementation (P=0.012); however, a nonsignificant increase was seen in thyroid volume in control group (P=0.832). Selenium supplementation can reduce thyroid nodule volume in euthyroid patients. Selenium; supplementation; thyroid; thyroid volume; thyroid nodule; euthyroid
{"title":"Effects of Selenium Supplementation on Thyroid Nodule Volume in Euthyroid Patients: A Randomized Clinical Trial","authors":"Zeid Zerehsaz, M. Yaghoubi, Ali Teimouri, Zohreh Mousavi, Mona Najaf Najafi, Ali Moradi, Masoud Mohebbi, A. Sahebkar","doi":"10.2174/0115748855283065240403073316","DOIUrl":"https://doi.org/10.2174/0115748855283065240403073316","url":null,"abstract":"\u0000\u0000Evaluating the Effect of Selenium Supplementation on Thyroid Nodule Volume in Euthyroid Patients\u0000\u0000\u0000\u0000Selenium is an essential trace element, which plays a role in regulation of the metabolism of thyroid hormones.\u0000\u0000\u0000\u0000This study was designed to evaluate the effect of selenium on the volume of thyroid nodules in euthyroid patients.\u0000\u0000\u0000\u0000In this triple-blinded clinical trial, a total of 60 euthyroid patients with benign thyroid nodules (solitary or multinodular goiter) and normal serum selenium were randomly divided into the case and control (n=30 each) groups. The case group received selenium 200 μg/day while the control group received placebo for 3 months. Thyroid ultrasound was used to measure thyroid nodule volume.\u0000\u0000\u0000\u0000Selenium supplementation (200 µg/day) retained the serum selenium levels of participants in the case group (P=0.251), while, the control group showed a significant drop in serum selenium levels (P=0.007). Moreover, the thyroid volume in case group showed a significant decrease after selenium supplementation (P=0.012); however, a nonsignificant increase was seen in thyroid volume in control group (P=0.832).\u0000\u0000\u0000\u0000Selenium supplementation can reduce thyroid nodule volume in euthyroid patients.\u0000\u0000\u0000\u0000Selenium; supplementation; thyroid; thyroid volume; thyroid nodule; euthyroid \u0000","PeriodicalId":11004,"journal":{"name":"Current Drug Therapy","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140697311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：